WB result of CD122 Recombinant Rabbit mAb
Primary antibody: CD122 Recombinant Rabbit mAb at 1/1000 dilution
Lane 1: Daudi whole cell lysate 20 µg
Lane 2: NK-92 whole cell lysate 20 µg
Lane 3: Karpas-299 whole cell lysate 20 µg
Lane 4: HuT-78 whole cell lysate 20 µg
Negative control: Daudi whole cell lysate
Secondary antibody: Goat Anti- rabbit IgG, (H+L), HRP conjugated at 1/10000 dilution
Predicted MW: 61 kDa
Observed MW: 75 kDa
CD122 Recombinant Rabbit mAb (S-3364-9)
CD122 Recombinant Rabbit mAb (S-3364-9)
Price:
Regular price
$100 USD
Regular price
Sale price
$100 USD
Unit price
per
For shipping services or bulk orders, you may request a quotation.
Secure checkout with
View full details
Product Details
Product Details
Product Specification
| Host | Rabbit |
| Antigen | CD122 |
| Synonyms | Interleukin-2 receptor subunit beta; IL-2 receptor subunit beta; IL-2R subunit beta; IL-2RB; High affinity IL-2 receptor subunit beta; Interleukin-15 receptor subunit betaImported; p70-75 (p75); IL15RB; IL2RB |
| Immunogen | Recombinant Protein |
| Location | Cell membrane |
| Accession | P14784 |
| Clone Number | S-3364-9 |
| Antibody Type | Recombinant mAb |
| Isotype | IgG |
| Application | WB |
| Reactivity | Hu |
| Positive Sample | NK-92, Karpas-299, HuT-78 |
| Purification | Protein A |
| Concentration | 2 mg/ml |
| Conjugation | Unconjugated |
| Physical Appearance | Liquid |
| Storage Buffer | PBS, 40% Glycerol, 0.05% BSA, 0.03% Proclin 300 |
| Stability & Storage | 12 months from date of receipt / reconstitution, -20 °C as supplied |
Dilution
| application | dilution | species |
| WB | 1:1000 | Hu |
Background
CD122, also known as the interleukin-2 receptor beta (IL-2Rβ), is a key component of the IL-2 receptor complex and plays a crucial role in regulating immune responses. It is expressed on the surface of various immune cells, including T cells and natural killer (NK) cells. CD122 is involved in mediating the effects of IL-2, which is essential for the proliferation and differentiation of T cells, as well as the maintenance of regulatory T cells (Tregs). Recent studies have shown that targeting CD122 with selective IL-2 complexes can reduce immunosuppression by Tregs and enhance antitumor immunity, making it a promising target for cancer immunotherapy.
Picture
Picture
Western Blot
